An NHLBI Workshop Report

Beyond Mortality

Future Clinical Research in Acute Lung Injury

Roger G. Spragg¹, Gordon R. Bernard², William Checkley³, J. Randall Curtis⁴, Ognjen Gajic⁵, Gordon Guyatt⁶, Jesse Hall⁷, Elliott Israel⁸, Manu Jain⁹, Dale M. Needham³, Adrienne G. Randolph¹⁰, Gordon D. Rubenfeld¹¹, David Schoenfeld¹², B. Taylor Thompson¹³, Lorraine B. Ware², Duncan Young¹⁴, and Andrea L. Harabin¹⁵

¹Department of Medicine, University of California, San Diego, San Diego California; ²Department of Medicine, Vanderbilt University Medical Center, Nashville Tennessee; ³Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland; ⁴Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Washington Harborview Medical Center, Seattle, Washington; ⁵Division of Pulmonary and Critical Care, Mayo Clinic, Rochester, Minnesota; ⁶Departments of Epidemiology and Biostatistics and Medicine, McMaster University, Hamilton, Ontario, Canada; ⁷Section of Pulmonary and Critical Care Medicine, University of Chicago Medical Center, Chicago Illinois; ⁸Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; ⁹Division of Pulmonary and Critical Care Medicine, Northwestern University, Chicago, Illinois; ¹⁰Children's Hospital Boston, Boston, Massachusetts; ¹¹Department of Medicine, University of Toronto, Toronto Ontario, Canada; ¹²Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts; ¹³Pulmonary and Critical Care Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; ¹⁴Adult Intensive Care, John Radcliffe Hospital, Headington, Oxford, United Kingdom; and ¹⁵Division of Lung Diseases, National Heart, Lung and Blood Institute, Bethesda, Maryland

Mortality in National Heart, Lung and Blood Institute-sponsored clinical trials of treatments for acute lung injury (ALI) has decreased dramatically during the past two decades. As a consequence, design of such trials based on a mortality outcome requires ever-increasing numbers of patients. Recognizing that advances in clinical trial design might be applicable to these trials and might allow trials with fewer patients, the National Heart, Lung and Blood Institute convened a workshop of extramural experts from several disciplines. The workshop assessed the current state of clinical research addressing ALI, identified research needs, and recommended: (1) continued performance of trials evaluating treatments of patients with ALI; (2) development of strategies to perform ALI prevention trials; (3) observational studies of patients without ALI undergoing prolonged mechanical ventilation; and (4) development of a standardized format for reporting methods, endpoints, and results of ALI trials.

Keywords: clinical trials; acute respiratory distress syndrome; pulmonary diseases; edema; inflammation

This report summarizes the findings of a workshop convened by the Division of Lung Diseases of the National Heart, Lung and Blood Institute (NHLBI) on August 5 and 6, 2009. The goal of the workshop was to assess the current state of clinical research addressing acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS), identify research needs, and develop recommendations for clinical research in the near future.

Data on mortality attributable to ALI are conflicting (1, 2), but both longitudinal observations at single institutions and the experience of the NHLBI ARDS Clinical Trials Network report a substantial decline over the past 2 decades. It should be noted

that mortality is often higher in observational studies, which do not exclude patients with high-risk comorbidities, than it is in interventional trials. Studies from the Network permit comparison of mortalities in patients of similar disease severity and source, and in these studies mortality has decreased from almost 40% in studies conducted in the mid to late 1990s (3, 4) to approximately 25% in the most recent reports (5–7) (Figure 1). Consequently, clinical trials powered to detect differences in mortality may require ever-increasing numbers of patients to detect significant relative risk reduction. The panel was convened to examine whether novel investigational strategies might allow trials to enroll fewer patients and to consider other types of clinical research that would advance the science and treatment of ALI. The group included pulmonary, critical care, and cardiovascular clinician-scientists experienced in the design and conduct of clinical research as well as experts in biostatistics and genetics. References provided herein are by no means exhaustive but are provided to illustrate key statements. Throughout the text, references to ALI include ALI and ARDS, the subset of ALI with more severe hypoxemia.

Panelists were asked to consider issues in the following areas:

- Current operational definitions of ALI and ARDS and study inclusion criteria
- Usefulness of biomarkers and genetic markers in studies of ALI
- Issues pertaining to patients without ALI or chronic lung disease who are in the ICU and receiving mechanical ventilation for more than 72 hours
- Importance of quality-of-life studies of ALI survivors
- Clinical study endpoints
- Feasibility of prevention trials
- Value of Phase II studies
- Trial design

DEFINITIONS AND STUDY INCLUSION CRITERIA

Descriptions of ALI and ARDS have existed since the Civil War. In 1994, a working definition of ALI and ARDS that is

(Received in original form January 7, 2010; accepted in final form February 4, 2010)

Supported by National Heart, Lung and Blood Institute, National Institutes of Health.

Other workshop participants include John H. Alexander, M.D. (Durham, North Carolina); Nancy Cox, Ph.D. (Chicago, Illinois); Lydia Gilbert-McClain, M.D., F.C.C.P. (FDA); David Reboussin, Ph.D. (Winston-Salem, North Carolina); Myron Waclawiw, Ph.D., and Colin Wu, Ph.D. (NHLBI).

Correspondence and requests for reprints should be addressed to Andrea L. Harabin, Ph.D., Division of Lung Diseases, NHLBI, NIH, 6701 Rockledge Drive, Bethesda, MD 20892-7952. E-mail: Harabin@nih.gov

Am J Respir Crit Care Med Vol 181, pp 1121–1127, 2010

Originally Published in Press as DOI: 10.1164/rccm.201001-0024WS on March 11, 2010

Internet address: www.atsjournals.org

Figure 1. Observed 60-day mortality reported for the NHLBI Acute Respiratory Distress Syndrome Clinical Trials Network studies. Study dates are the midpoint of the patient accrual periods. Acute Respiratory Distress Syndrome Management with Lower versus Higher Tidal Volume (ARMA); ARMA-6 and ARMA-12 are groups receiving 6 or 12 ml tidal volume/kg predicted body weight (3). Data for Assessment of Low tidal Volume and Elevated End-expiratory Volume to Obviate Lung Injury (ALVEOLI) (4), Fluid and Catheter Treatment Trial (FACTT) (5), Albuterol for the Treatment of ALI (ALTA) (52), and Omega-3 Fatty Acid, Gamma-Linolenic Acid, and Antioxidant Supplementation in the Management of ALI or ARDS (OMEGA) (53) were obtained from the study reports. Studies included a total of 2,944 patients. ARDS Network studies that are not included had significant coenrollment with the studies shown. The reduction in mortality remains significant if ARMA-12 is excluded from the analysis.

now widely used was developed by the American European Consensus Conference (AECC) (8). This definition depends on evaluation of gas exchange, the chest radiograph, and exclusion of a cardiogenic cause for lung edema. Although facilitating study of comparable patient populations, this definition is open to criticism. For example, conditions under which gas exchange is measured, such as level of positive end-expiratory pressure, are not specified and often significantly influence the measurement (9). Widespread use of oximetry may replace the use of arterial blood gas measurements (10). Assessment of cardiac function has evolved as use of Swan-Ganz catheters has diminished and use of serum brain natriuretic peptide levels to assess cardiac function has increased. Interpretation of chest radiographs is inconsistent, although may be made more consistent with training (11). Use of the AECC definitions results in recruitment of populations of patients with heterogeneous predispositions for development of ALI and with a spectrum of comorbidities that may influence outcome. Furthermore, categorizing patients with ALI by gas exchange impairment into ARDS and non-ARDS groups does not necessarily identify patients with different underlying disease mechanisms, pathophysiology, prognosis, or responsiveness to treatment. A fundamental challenge for investigators is that patients with ALI are likely to have significant heterogeneity in each of these dimensions.

Rather than propose new definitions of ALI or ARDS, the panel advocated flexibility in deciding inclusion criteria. Investigators should consider modifying inclusion and exclusion criteria for individual studies, basing those modifications when possible on results of Phase II studies or application of relevant biomarkers or genetic information. Strategies that would enrich study populations with patients likely to respond to a treatment under study may help define appropriate study populations. For

example, study of lung recruitment or use of high positive end-expiratory pressure might require the presence of extensive bilateral opacities on the chest radiograph or CT scan, profound gas exchange abnormalities, and evidence that the lungs are acutely recruitable, whereas studies of pharmacologic interventions with low potential for toxicity might allow enrollment of patients with only modest gas exchange abnormalities and less extensive chest radiographic abnormalities. Exclusion of patients with comorbidities expected to influence the study endpoints but unlikely to respond to the study treatment may be appropriate. Inclusion and exclusion criteria, however, should be reproducibly and feasibly applicable by front-line clinicians. The panel recognized that limiting eligibility may make identification of target populations more challenging, make achievement of target sample size more difficult, and may limit the generalizability of results. Furthermore, the hypotheses underlying exclusion of patients on a genetic or physiologic basis may not, in fact, be valid, and if they are not, their spuriousness may never be discovered. Some exclusion criteria (e.g., those based on genetic testing) may be particularly problematic if there is little prospect of the requisite tests being widely and rapidly available. Additional testing also has the added risk of increasing study costs without benefit. Large, simple trials with broad eligibility criteria may in many instances be worthy of consideration.

Some interventions are appropriately applied across a heterogeneous and large group of patients. These often include process-of-care studies, such as those targeting ventilator or fluid management. Other interventions are better evaluated in groups of patients who share common pathogenetic mechanisms that result in ALI. For example, study of immune modulating therapy for patients with ALI triggered by influenza virus infection would properly be performed in patients demonstrated to be infected with that agent. Both large simple trials and more focused studies targeted at specific subgroups are needed.

Mortality and incidence of ALI differ substantially over the spectrum from infants to aged adults (12). The incidence and mortality in young adults and children is similar, and is markedly lower than in the elderly. Studies of ALI in adults outnumber pediatric ALI studies, but there have been some recent noted successes in the latter group (13, 14). It may not be appropriate to include all patients across the entire age range in all trials. To increase the evidence supporting use of ARDS treatments for children, recent recommendations have been published for use of Bayesian and other novel statistical approaches for combining data from children and from adults in ARDS clinical trials (15).

BIOMARKERS IN STUDIES OF ALI

Biomarkers might potentially be used to predict outcome, identify subgroups with different response to therapy, or serve as surrogate endpoints. A variety of plasma and urine biomarkers are associated with mortality in large multicenter studies of ALI (Table 1)(16–18). Inflammatory markers (IL-6, IL-8, tumor necrosis factor receptors 1 and 2, urine nitric oxide), epithelial cell markers (receptor for advanced glycation end-products, surfactant protein D), adhesion molecules (intercellular adhesion molecule), markers of endothelial injury (von Willebrand factor antigen), extracellular matrix (desmosine) and coagulation proteins (protein C, plasminogen activator inhibitor 1) were all associated independently with mortality in the NHLBI ARDS Clinical Trials Network study of a lung-protective ventilation strategy (3). Procollagen peptide III has been shown to be correlated with outcome (19). However, only

TABLE 1. BIOMARKERS IN MULTICENTER CLINICAL TRIALS OF ACUTE LUNG INJURY

Pathobiology	Biomarker	Source	Abnormality in ALI/ARDS	Predictive of Outcome
Endothelium	VWf-Ag	Plasma	Increased	+
Endothelium & epithelium	ICAM-1	Plasma	Increased	+
Epithelium	SP-A	Plasma	No change	—
	SP-D	Plasma	Increased	+
	RAGE	Plasma	Increased	+
Extracellular matrix	Desmosine	Urine	Increased	+
	IL-6	Plasma	Increased	+
	IL-8	Plasma	Increased	+
	IL-10	Plasma	Increased	—
	sTNF- α & II	Plasma	Increased	+
Inflammation	Nitric oxide	Urine	Decreased	+
	Protein C	Plasma	Decreased	+
	PAI-1	Plasma	Increased	+
Coagulation	PCP	Lavage	Increased	+
Fibroblast activation				

Definition of abbreviations: ALI = acute lung injury; ARDS = acute respiratory distress syndrome; ICAM-1 = intercellular adhesion molecule 1; PAI-1 = plasminogen activator inhibitor 1; RAGE = receptor for advanced glycation end-products; SP-A = surfactant protein A; SP-D = surfactant protein D; sTNF- α & II = soluble tumor necrosis factor receptors I and II; VWf-Ag = von Willebrand factor antigen; PCP = procollagen peptide III; + = positive result; — = negative result.

Adapted from Reference 18, wherein specific references may be found.

a few of these markers (surfactant protein-D, IL-6, IL-8, protein C, receptor for advanced glycation end-products, and urine nitric oxide) had changes associated with the low tidal volume treatment effect, and the differences were modest, suggesting that we have yet to identify good surrogate biomarkers for ventilator treatment effects (17, 20–24).

Biomarkers have the potential to allow selection of patient groups for interventional studies that may have a higher predicted mortality than the general population of patients with ALI, thereby reducing the required sample size. In addition, biomarkers could potentially be useful in facilitating both the prediction and early diagnosis of ALI, allowing earlier testing of preventive and therapeutic interventions. For these applications, information derived from combinations of biomarkers is superior to the use of individual biomarkers (16), but the added value of biological markers over clinical predictors is currently small, and further investigation is warranted. Conducting proteomic studies for discovery of novel biomarkers for diagnosis and prognosis in ALI is an attractive goal, although appropriate sample collection and preparation is of critical importance (25).

The group noted that surrogate biomarkers of outcome, which may or may not be in the causal pathway of a disease, and which might substitute for a clinical outcome, have been very difficult to find and validate. Even well-studied markers, such as lipid levels in cardiovascular diseases, have been shown in some studies to be unreliable (26, 27).

Genetic studies may help elucidate pathogenesis, identify clinically important subgroups, and provide explanations for observed variability in outcomes or responses to treatment. Genetic factors can influence the outcomes and adverse events in interventional studies of ALI in a variety of ways. Important genetic factors may be related to: susceptibility to the primary disease; drug metabolism, transport, or receptor interaction; or the biological pathway being targeted by the intervention. Pharmacogenetic effects tend to be much larger than primary disease genetic effects, and therefore may be easier to detect. Many panel members agreed that acquiring specimens for genetic analysis from patients enrolled in large clinical trials is of significant value, and that even when trials are negative,

genetic information can be useful. However, it was pointed out that the complexity of the ALI syndrome, the strong influence of environment on development and outcome of ALI, and the challenges inherent in analyzing massive amounts of information may limit the value of genetic studies. At present there are studies on individual gene polymorphisms (28–30) showing association with ALI, and large genetic discovery efforts (genome-wide association studies, GWAS) are in progress. Although large sample sizes are usually required for GWAS, if there are genome–phenome interactions with large effects, smaller samples may detect such effects. In addition, samples may be combined across studies, depending on outcomes, to enlarge the effective sample. Children with ALI present the opportunity to use family-based statistical genetics approaches and offer a more robust control group, although sample sizes for family-based studies are usually much larger than in case-control studies.

OTHER VENTILATED PATIENTS

Both the number and age of patients in the ICU undergoing prolonged mechanical ventilation (e.g., greater than 24 h) are increasing (31, 32) (Figure 2), yet little is known about this population if ALI is not present. The fraction of ventilated patients with ALI is relatively small (33) and some patients develop ALI after intubation and ventilation for other indications, making studies that clarify the risk factors for this evolution attractive. It would be desirable to develop a greater understanding of the demographics, pathology, and outcomes of these patients, including the frequency with which they progress to ALI (34). Observational studies to discover meaningful phenotypes should be considered. Interventional studies, including wider application of lung-protective ventilation early in the course of respiratory failures of various types, could prove to be valuable in reducing the incidence of ALI. A variety of care processes is common in this heterogeneous group of patients with respiratory failure and includes noninvasive ventilation, sedation, nutrition, and immobilization. Very little evidence underlies best practices with these treatments, and comparative effectiveness research may be valuable for evaluating these processes. Coordination of studies across international boundaries offers the possibility of taking advantage of population-based databases that currently exist in countries with single-payer health-care systems. Moreover, design of a minimum data set for collection on these patients, as part of hospital- or ICU-based clinical information systems, may be beneficial in addressing fundamental gaps in knowledge regarding these patients.

QUALITY-OF-LIFE STUDIES OF ALI SURVIVORS

It is now clear that survivors of critical illness and ALI experience a substantial and prolonged negative impact across many domains of their subsequent quality of life (35–37). Survivors have deficits in functional status, physical and psychological symptoms, and cognition (38). There are currently no randomized trials of interventions during the period of critical illness showing improved quality-of-life outcomes. For most studies of ALI, quality-of-life measurements will serve as secondary, rather than primary, endpoints. Quality of life as a primary outcome may be most appropriate in Phase III and IV trials when there is a low predicted mortality rate or in circumstances where the intervention may affect multiple domains evaluated by standard quality-of-life instruments. Assessing quality of life after hospital discharge in ALI survivors also may contribute to cost–utility analyses (39).

Figure 2. Actual and projected number of non-cardiac surgery, mechanically ventilated patients in Ontario, 1992 through 2026, based on actual data for 1992 and 2000 and projections, by 5-year interval, from 2006 to 2026. Projections were derived using direct standardization of the age-specific and sex-specific incidence of mechanical ventilation in 2000 and three population (pop.) growth scenarios from Statistics Canada and one scenario with both low population growth and a 20% decrease in incidence for 85 years and older and a 10% decrease for 75- to 84-year-old Ontario residents. (Reproduced with permission from Reference 32.)

For these reasons, quality-of-life assessment (40) should be considered a fundamental component of large-scale ALI studies. Quality of life measured using validated instruments and administered via a centralized telephone call center may be a cost-effective, feasible, and valid component of large multisite trials. Generic measures in use today, such as the Short Form-36 (SF36), are appropriate for ALI studies, and development of ALI-specific quality-of-life measures is unlikely to be needed. Further work is required to develop and validate methods for estimating individuals' premorbid baseline function, enhance complete data collection during both the acute and follow-up phases of illness, and evaluate measures in pediatric illness.

CLINICAL STUDY ENDPOINTS

The group agreed that mortality continues to be the critical outcome in studies of specific treatments for ALI. When considering other endpoints of "clinical significance," it is important to note that there is little clarity or consensus regarding the meaning of that term (41). Certain patient-centered or "patient-important" outcomes may be easier to define and agree on. However, complexity is provided by variability in patient and provider knowledge and preferences. For patients with ALI, survival, cognitive function, pulmonary function, and quality of life are clearly important, whereas substantial decreases in time on a ventilator, in the ICU, or in hospital may also have some, though likely less, importance. Endpoints such as organ failure, if unaccompanied by changes in mortality or quality of life, are also likely to be of lesser importance from patients' perspectives.

There are no proven surrogate measures for mortality in ALI. For example, treatments that improve oxygenation in ALI do not reliably result in a reduction in mortality (3, 4, 42, 43). This observation is consistent with other treatments in critical illness where organ failure reversal does not reliably correlate with mortality reduction (44–46). Duration of mechanical ventilation or the number of days alive and free of mechanical ventilation during the first 28 days after diagnosis with ALI (referred to as "ventilator-free days"), are poten-

tially biased outcomes because the decision to discontinue mechanical ventilation is often subjective unless driven by an explicit protocol. The number of ventilator-free days was implemented to account for the reduced duration of mechanical ventilation in patients with early death. However, there are several known limitations to use of ventilator-free days as an outcome measure, and few demonstrated advantages. Studies that show no change between treatment and control groups in ventilator-free days can have a significant difference in mortality (14). Furthermore, this outcome measure is not particularly patient centered, is not a surrogate for cost, and assigns equal weights to death and prolonged mechanical ventilation. When the number of ventilator-free days to day 28 is used as a primary endpoint, investigators must also include mortality as a coprimary endpoint, because the former metric may fail to achieve statistical significance when mortality does (14). If the decision is made to have these outcomes as coprimary endpoints, studies must be powered for both, and creation of stopping rules becomes considerably more complex, though attainable (3).

Use of a primary composite endpoint as a strategy for reducing sample size must be considered with great care. Composite endpoints can be of value only when they satisfy several conditions. Each component should be of similar importance to the patient, the more and less patient-important outcomes should occur with equal frequency, and they should have similar risk reductions in response to effective interventions (47). Without these conditions, composite outcomes can be misleading. For example, a composite endpoint may be predominately determined by a component of lesser patient importance, such as time on mechanical ventilation, whereas a component of greater patient importance, such as mortality, shows no change or even potential harm.

The distinction between survival and mortality as an endpoint is often lost in reports of clinical ALI studies. The former is correctly applied to the length of time between the onset of ALI and death, whereas the latter is a measure of those who have died at a specific point in time. Survival is of limited value in ARDS clinical trials, because the timing of death is often determined by comorbid conditions and by decisions regarding withdrawal of

life support. Further, death after a few days may not be a worse outcome than death after a few weeks.

The panel concluded that mortality remains the essential endpoint in ALI trials, but that measures of longer-term quality of life, functional status, and cost should also be measured given the high frequency of important and long-lasting deficiencies in those outcomes.

PREVENTION TRIALS

When considering trials that focus on prevention of ALI, it has been customary to identify populations at high risk of developing ALI, such as patients with sepsis, and consider them as the target population. As the interval between risk exposure and development of ALI may be very short, and as only a small percentage of patients at risk actually proceed to develop ALI, the number of patients required to study treatments to modify the course of ALI has appeared prohibitive. However, several recent developments may alter this conclusion. These include broad application of informatics technology to identify high-risk patients across many centers, identification of very specific populations at great risk (such as pediatric recipients of bone marrow transplants or certain postoperative patient groups), and development of methods to accomplish cluster randomization of critical care units or hospitals across many medical centers and medical disciplines. Identification of patients at risk early in the course of their illness (e.g., in the emergency department or operating room) may allow earlier implementation of ALI prevention strategies.

Interventions appropriate for testing in prevention trials should be able to be rapidly administered, inexpensive, and safe. Such interventions may occasionally be identified in hospital quality assurance programs.

Other prevention trials to consider include those designed to decrease the incidence of specific adverse outcomes of ALI, including cognitive, psychological, and neuromuscular complications.

VALUE OF PHASE II STUDIES IN ALI

The group considered the status and value of Phase II studies that screen new therapeutic approaches to provide the rationale for larger Phase III efficacy trials of promising interventions. Phase II randomized clinical trials are preferable to Phase II trials that use historical controls. Useful endpoints for Phase II studies include those that indicate safety, elucidate mechanism of action, and provide suggestion of efficacy. Phase II studies can be investigator initiated and performed at a single site, or can have a more complex recruiting structure. The ARDS Network has generally done Phase II/III trials, designed such that new drug therapies can be tested in Phase II and retained in a Phase III trial if prespecified efficacy, safety, and proof-of-concept outcomes have been demonstrated. The Phase III trials often have a factorial design, include a process-of-care question, and have a fairly liberal futility stopping boundary. If the initial results at the first interim analysis are not strongly positive, the trial is stopped. The opportunity cost of demonstrating unequivocally that a novel drug is not efficacious is considered high when other agents are available to be tested. The panel discussed whether it would be better to conduct a number of Phase II studies simultaneously, perhaps with a common control group, to choose the most promising for further study, but found that approach to be complex and controversial. In general, the group believed there are a number of promising therapies available for testing and that Phase II/III studies should continue to be a priority.

TRIAL DESIGN

All clinical trials are becoming increasingly complex, slower, and costly. The clinical trial is a tool appropriate for many, but not all, research questions. The design depends on whether the objective is determination of efficacy or discovery of mechanisms. Study size is determined by event rate, the size of the treatment effect expected, the desired precision of the answer (Type II error or probability of falsely rejecting a true hypothesis), and availability of resources. Bayesian trial designs have the potential to reduce sample size (48). The group warned that excessive reliance on a single primary outcome and a single *P* value is perilous. Instead, multiple results from a clinical trial or trials should be considered for subsequent clinical decision making, including evaluation of secondary endpoints and plausible biomarkers. The panel acknowledged that pragmatism is important in designing trials. Often there must be a compromise between assumptions and precision, on the one hand, and feasibility and available resources on the other.

Most trials in ALI have been explanatory or mechanistic in nature, performed to determine the impact of an intervention on clinical outcomes and biological endpoints. The participants may be highly selected and the intervention is usually strictly defined. Studies under such conditions should be reproducible and give mechanistic insights to guide clinical decision making.

In contrast, large simple trials, which are often designed as pragmatic trials addressing patient-important outcomes in a real-world context, are an appealing possibility in critical care. As opposed to smaller Phase III efficacy trials, these studies include a sample size chosen to detect changes in outcomes that are unequivocally patient-important and to detect relatively small, but still important, effect sizes. They generally have broad inclusion and minimal exclusion criteria, require limited data collection, and permit patient management to remain as close as possible to normal clinical practice. There are examples of unequivocal practical trials in critical care (49, 50). Enthusiasm for large simple trials may be tempered by the limited new knowledge that is often obtained.

The group recognized that design of clinical trials is to some extent an art. Design must take into account practical issues, such as patient availability, time of accrual, and available budget. With the current status of ALI care, it is likely that few if any sponsors have the resources to support appropriately sized studies to detect small mortality differences. Similarly, practical issues usually preclude multiple studies of the same intervention. Multiple smaller studies of similar nature, analyzed by meta-analysis, can provide guidance for clinical decision making. Prospectively planned individual patient metaanalysis is a particularly powerful tool, and probably the only way to reliably define subgroup effects. Stopping trials for futility is controversial (51). Although stopping may provide the opportunity for performing additional studies of new interventions, it may have a negative impact on the ability to perform subsequent individual patient data metaanalyses. International cooperation is recommended so that similar studies with common minimum data sets can be conducted in multiple countries.

PRIORITIZED RECOMMENDATIONS AND CONCLUSIONS

- Highest priority is suggested for large Phase III studies primarily designed to optimize current ICU-based care and pharmacologic interventions. These studies will also permit continued exploration of the usefulness of biomarkers and genetic factors to identify subpopulations, predict outcome, facilitate diagnosis, describe pharmaco-

genomic effects that influence response to therapy, and provide insight into mechanisms of lung injury. Collection of appropriate samples, including plasma, urine, and DNA from study participants, is essential. Study of the impact of interventions on long-term quality of life and other functional outcomes after hospital discharge is of high value and should be a fundamental part of Phase III trials.

- Phase II or Phase II/III studies should continue, with the aims of identifying and testing the many promising new interventions that exist and providing rationale for larger efficacy studies.
- The capability to perform ALI prevention trials should be developed. This development may involve collaboration with other clinical groups (e.g., emergency department physicians, anesthesiologists, trauma surgeons) and will be facilitated by new informatics technologies, such as the electronic medical record.
- Observational studies of patients without ALI who are undergoing mechanical ventilation for longer than 72 hours are recommended. Such studies may improve understanding of how critical care resources are being spent, facilitate process-of-care studies and effectiveness research, allow assessment of the impact of premorbid conditions on outcome, and suggest outcome measures that are alternatives to mortality.

In conclusion, progress in understanding and treating ALI has been incremental and is likely to remain so. The preponderance of the evidence, including clinical and mechanistic studies, should be used to guide clinical decision making. The reporting and interpretation of results of ALI clinical studies could be improved by use of a standardized description of methods, endpoints, and results. A standardized format in ALI trials for collecting data, including long-term quality-of-life and functional status outcomes, would facilitate patient-level metaanalyses from multiple trials and enhance collaborative efforts, and development of such an instrument is recommended.

Conflict of Interest Statement: R.G.S. has received consultancy fees from Nycomed GmbH (\$10,001–\$50,000); he is employed by the University of California, San Diego (\$10,001–\$50,000) and has received advisory board fees from Veterans Medical Research Foundation (\$10,001–\$50,000). G.R.B. has no financial relationship with a commercial entity that has an interest in the subject of this manuscript. W.C. has no financial relationship with a commercial entity that has an interest in the subject of this manuscript. J.R.C. has received royalties from Oxford University Press (up to \$1,000); he has received sponsored grants from NIH (over \$100,000). O.G. has no financial relationship with a commercial entity that has an interest in the subject of this manuscript. G.G. has received consultancy fees from Up To Date (\$60,000); he has received expert witness fees from Fosamax (\$8,000). J.H. has received expert witness fees from various law firms and insurance companies (\$50,001–\$100,000); he has received industry-sponsored grants from Eli Lilly (\$10,001–\$50,000) and Johnson and Johnson (\$10,001–\$50,000); he has received royalties from McGraw Hill (\$10,001–\$50,000); he owns health care focused mutual funds (over \$100,000); he has received advisory board fees from ATS (up to \$10,000), lecture fees as ATS SOTA director (\$1,000–\$5,000), and fees from SEEK Committee as a contributor to CME content (\$5,001–\$10,000). He is also an Editorial Board member of both *Chest* and *Critical Care Medicine*. E.I. has no financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.J. has received sponsored grants from the Cystic Fibrosis Foundation (\$50,001–\$100,000). D.M.N. has received consultancy fees from Passy Muir Inc. (\$1,000–\$5,000) and Bay Back Strategies LLC (up to \$1,000); he has received sponsored grants from NIH (over \$100,000). A.G.R. has received consultancy fees from Eisai Pharmaceuticals (up to \$1,000); he has received advisory board fees from Discovery Laboratories (\$1,000–\$5,000) and industry-sponsored grants from MedImmune Inc. (\$10,001–\$50,000). G.D.R.'s institution has received the following grants from nonprofit agencies or foundations: National Institutes of Health (approximately \$10 million), Robert Wood Johnson Foundation (approximately \$500,000); his institution has received the following grants from for-profit companies: Advanced Lifeline Systems (approximately \$150,000), Siemens (approximately \$50,000), Bayer (approximately \$10,000), Byk-Gulden (approximately \$15,000), Astra-Zeneca (approximately \$10,000). He has received the

following honoraria, consulting, editorship, and DSMB membership fees: Bayer (approximately \$500), DHD (approximately \$1,000), Lilly (approximately \$5,000), Hospira (approximately \$15,000), Cerner (approximately \$5,000), Pfizer (approximately \$1,000), KCI (approximately \$7,500), American Association for Respiratory Care (approximately \$10,000), American Thoracic Society (approximately \$7,500), National Institutes for Health (approximately \$500), Alberta Heritage Foundation for Medical Research (approximately \$250), Faron Pharmaceuticals (approximately \$5,000), and Cerus Corporation (approximately \$11,000). D.S. has no financial relationship with a commercial entity that has an interest in the subject of this manuscript. B.T.T. has received consultancy fees from Eli Lilly (\$10,001–\$50,000), AstraZeneca (\$5,001–\$10,000), and Abbott (\$5,001–\$10,000); he has received lecture fees from Eli Lilly (\$1,001–\$5,000). He has received various sponsored grants from NHLBI (\$25,000–\$110,000), and advisory board fees from NHLBI (\$1,001–\$5,000). L.B.W. has received industry-sponsored grants from Luminex (\$1,001–\$5,000) and Sirius Genomics (\$10,001–\$50,000); he has received sponsored grants from NIH (over \$100,000). D.Y. has no financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.L.H. has no financial relationship with a commercial entity that has an interest in the subject of this manuscript.

References

1. Zambon M, Vincent JL. Mortality rates for patients with acute lung injury/ARDS have decreased over time. *Chest* 2008;133:1120–1127.
2. Phua J, Badia JR, Adhikari NK, Friedrich JO, Fowler RA, Singh JM, Scales DC, Stather DR, Li A, Jones A, *et al*. Has mortality from acute respiratory distress syndrome decreased over time?: a systematic review. *Am J Respir Crit Care Med* 2009;179:220–227.
3. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med* 2000;342:1301–1308.
4. Brower RG, Lanken PN, MacIntyre N, Matthay MA, Morris A, Ancukiewicz M, Schoenfeld D, Thompson BT. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. *N Engl J Med* 2004;351:327–336.
5. Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, Connors AFJ, Hite RD, Harabin AL. Comparison of two fluid-management strategies in acute lung injury. *N Engl J Med* 2006;354:2564–2575.
6. Wheeler AP, Bernard GR, Thompson BT, Schoenfeld D, Wiedemann HP, deBoisblanc B, Connors AFJ, Hite RD, Harabin AL. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. *N Engl J Med* 2006;354:2213–2224.
7. Erickson SE, Martin GS, Davis JL, Matthay MA, Eisner MD, for the NIH NHLBI ARDS Network. Recent trends in acute lung injury mortality: 1996–2005. *Crit Care Med* 2009;37:1574–1579.
8. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, LeGall JR, Morris A, Spragg R. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. *Am J Respir Crit Care Med* 1994;149:818–824.
9. Villar J, Perez-Mendez L, Lopez J, Belda J, Blanco J, Saralegui I, Suarez-Sipmann F, Lubillo S, Kacmarek RM. An early PEEP/FIO₂ trial identifies different degrees of lung injury in patients with acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2007;176:795–804.
10. Rice TW, Wheeler AP, Bernard GR, Hayden DL, Schoenfeld DA, Ware LB. Comparison of the SpO₂/FIO₂ ratio and the PaO₂/FIO₂ ratio in patients with acute lung injury or ARDS. *Chest* 2007;132:410–417.
11. Rubenfeld GD, Caldwell E, Granton J, Hudson LD, Matthay MA. Interobserver variability in applying a radiographic definition for ARDS. *Chest* 1999;116:1347–1353.
12. Ely EW, Wheeler AP, Thompson BT, Ancukiewicz M, Steinberg KP, Bernard GR. Recovery rate and prognosis in older persons who develop acute lung injury and the acute respiratory distress syndrome. *Ann Intern Med* 2002;136:25–36.
13. Curley MA, Hibberd PL, Fineman LD, Wypij D, Shih MC, Thompson JE, Grant MJ, Barr FE, Cvijanovich NZ, Sorce L, *et al*. Effect of prone positioning on clinical outcomes in children with acute lung injury: a randomized controlled trial. *JAMA* 2005;294:229–237.
14. Willson DF, Thomas NJ, Markovitz BP, Bauman LA, DiCarlo JV, Pon S, Jacobs BR, Jefferson LS, Conaway MR, Egan EA. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. *JAMA* 2005;293:470–476.
15. Schoenfeld DA, Zheng H, Finkelstein DM. Bayesian design using adult data to augment pediatric trials. *Clin Trials* 2009;6:297–304.

16. Ware LB, Koyama T, Billheimer DD, Wu W, Bernard GR, Thompson BT, Brower RG, Standiford TJ, Martin TR, Matthay MA. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. *Chest* 2010;137:288–296.
17. McClintock D, Zhuo H, Wickersham N, Matthay MA, Ware LB. Biomarkers of inflammation, coagulation and fibrinolysis predict mortality in acute lung injury. *Crit Care* 2008;12:R41.
18. Levitt JE, Gould MK, Ware LB, Matthay MA. The pathogenetic and prognostic value of biologic markers in acute lung injury. *J Intensive Care Med* 2009;24:151–167.
19. Clark JG, Milberg JA, Steinberg KP, Hudson LD. Type III procollagen peptide in the adult respiratory distress syndrome. Association of increased peptide levels in bronchoalveolar lavage fluid with increased risk for death. *Ann Intern Med* 1995;122:17–23.
20. Calfee CS, Ware LB, Eisner MD, Parsons PE, Thompson BT, Wickersham N, Matthay MA. Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. *Thorax* 2008;63:1083–1089.
21. Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, Eisner MD. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. *Crit Care Med* 2007;35:1821–1828.
22. Parsons PE, Eisner MD, Thompson BT, Matthay MA, Ancukiewicz M, Bernard GR, Wheeler AP. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. *Crit Care Med* 2005;33:1–6.
23. Parsons PE, Matthay MA, Ware LB, Eisner MD. Elevated plasma levels of soluble TNF receptors are associated with morbidity and mortality in patients with acute lung injury. *Am J Physiol Lung Cell Mol Physiol* 2005;288:L426–L431.
24. Eisner MD, Parsons P, Matthay MA, Ware L, Greene K. Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. *Thorax* 2003;58:983–988.
25. Gerszten RE, Accurso F, Bernard GR, Caprioli RM, Klee EW, Klee GG, Kullo I, Laguna TA, Roth FP, Sabatine M, *et al.* Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs. *Am J Physiol Lung Cell Mol Physiol* 2008;295:L16–L22.
26. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. *J Am Coll Cardiol* 2004;43:1439–1444.
27. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, *et al.* Effects of torcetrapib in patients at high risk for coronary events. *N Engl J Med* 2007;357:2109–2122.
28. Howrylak JA, Dolinay T, Lucht L, Wang Z, Christiani DC, Sethi JM, Xing EP, Donahoe MP, Choi AM. Discovery of the gene signature for acute lung injury in patients with sepsis. *Physiol Genomics* 2009;37:133–139.
29. Kamp R, Sun X, Garcia JG. Making genomics functional: deciphering the genetics of acute lung injury. *Proc Am Thorac Soc* 2008;5:348–353.
30. Gao L, Barnes KC. Recent advances in genetic predisposition to clinical acute lung injury. *Am J Physiol Lung Cell Mol Physiol* 2009;296:L713–L725.
31. Carson SS, Cox CE, Holmes GM, Howard A, Carey TS. The changing epidemiology of mechanical ventilation: a population-based study. *J Intensive Care Med* 2006;21:173–182.
32. Needham DM, Bronskill SE, Calinawan JR, Sibbald WJ, Pronovost PJ, Laupacis A. Projected incidence of mechanical ventilation in Ontario to 2026: preparing for the aging baby boomers. *Crit Care Med* 2005;33:574–579.
33. Luhr OR, Antonsen K, Karlsson M, Aardal S, Thorsteinsson A, Frostell CG, Bonde J. Incidence and mortality after acute respiratory failure and acute respiratory distress syndrome in Sweden, Denmark, and Iceland. The ARF Study Group. *Am J Respir Crit Care Med* 1999;159:1849–1861.
34. Gajic O, Dara SI, Mendez JL, Adesanya AO, Festic E, Caples SM, Rana R, St Sauver JL, Lymp JF, Afessa B, *et al.* Ventilator-associated lung injury in patients without acute lung injury at the onset of mechanical ventilation. *Crit Care Med* 2004;32:1817–1824.
35. Davidson TA, Caldwell ES, Curtis JR, Hudson LD, Steinberg KP. Reduced quality of life in survivors of acute respiratory distress syndrome compared with critically ill control patients. *JAMA* 1999;281:354–360.
36. Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, Al-Saidi F, Cooper AB, Guest CB, Mazer CD, Mehta S, *et al.* One-year outcomes in survivors of the acute respiratory distress syndrome. *N Engl J Med* 2003;348:683–693.
37. Dowdy DW, Eid MP, Dennison CR, Mendez-Tellez PA, Herridge MS, Guallar E, Pronovost PJ, Needham DM. Quality of life after acute respiratory distress syndrome: a meta-analysis. *Intensive Care Med* 2006;32:1115–1124.
38. Mikkelsen ME, Shull WH, Biester RC, Taichman DB, Lynch S, Demissie E, Hansen-Flaschen J, Christie JD. Cognitive, mood and quality of life impairments in a select population of ARDS survivors. *Respirology* 2009;14:76–82.
39. Graf J, Wagner J, Graf C, Koch KC, Janssens U. Five-year survival, quality of life, and individual costs of 303 consecutive medical intensive care patients—a cost-utility analysis. *Crit Care Med* 2005;33:547–555.
40. Cox HL, Laupland KB, Manns BJ. Economic evaluation in critical care medicine. *J Crit Care* 2006;21:117–124.
41. Cravens SMR. The usage and meaning of “clinical significance” in drug-related litigation. *Wash Lee Law Rev* 2009;59:553–596.
42. Adhikari NK, Burns KE, Friedrich JO, Granton JT, Cook DJ, Meade MO. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. *BMJ* 2007;334:779.
43. Taccone P, Pesenti A, Latini R, Polli F, Vagginelli R, Mietto C, Caspani L, Raimondi F, Bordone G, Iapichino G, *et al.* Prone positioning in patients with moderate and severe acute respiratory distress syndrome. *JAMA* 2009;302:1977–1984.
44. Bakker J, Grover R, McLuckie A, Holzapfel L, Andersson J, Lodato R, Watson D, Grossman S, Donaldson J, Takala J. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144–002). *Crit Care Med* 2004;32:1–12.
45. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, *et al.* Intensive versus conventional glucose control in critically ill patients. *N Engl J Med* 2009;360:1283–1297.
46. Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. *Ann Intern Med* 2005;142:510–524.
47. Guyatt GH, Montori FM, Ferreira-Gonzalez I, Busse JW, Schunemann HJ, Jaeschke R, Permyer-Miranda G. Composite endpoints. In: Users' guides to the medical literature. Guyatt GH, Rennie D, Meade MO, Cook DJ, editors. Columbus, OH: McGraw-Hill; 2008. pp. 237–248.
48. Berry DA. Bayesian clinical trials. *Nat Rev Drug Discov* 2006;5:27–36.
49. Sakr Y, Vincent JL, Reinhart K, Payen D, Wiedermann CJ, Zandstra DF, Sprung CL. Use of the pulmonary artery catheter is not associated with worse outcome in the ICU. *Chest* 2005;128:2722–2731.
50. Harvey S, Harrison DA, Singer M, Ashcroft J, Jones CM, Elbourne D, Bampton W, Williams D, Young D, Rowan K. Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. *Lancet* 2005;366:472–477.
51. Schoenfeld DA. Pro/con clinical debate: It is acceptable to stop large multicentre randomized controlled trials at interim analysis for futility. Pro: futility stopping can speed up the development of effective treatments. *Crit Care* 2005;9:34–36.
52. Matthay MA, Brower RG, Thompson BT, Schoenfeld D, Eisner MD, Carson S, Moss M, Douglas I, Hite D, MacIntyre N, *et al.* Randomized, placebo-controlled trial of an aerosolized beta-2 adrenergic agonist (Albuterol) for the treatment of acute lung injury. *Am J Respir Crit Care Med* 2009;179:A2166.
53. Rice TW, Thompson BT, Smoot E, Wheeler AP, for the NHLBI ARDS Network of Investigators. Omega-3 (n-3) fatty acid, gamma-linolenic acid (GLA) and anti-oxidant supplementation in acute lung injury (OMEGA trial). *Crit Care Med* 2009;37:A408.